AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20554869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 0
Study 20554869 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 0
Study 20554869 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Yohimbine (combined)
Number of subjects: 0
Study 17511931 — intervention group
Group type: COMPARATOR
Intervention: Intervention not specified
Number of subjects: 0
Study 16229114 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg
Number of subjects: 312
Study 16229114 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 16 mg
Number of subjects: 312
Study 16229114 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg + Hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 312
Study 16229114 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 16 mg + Hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 312
Study 16229114 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 312
Study 11973171 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous insulin infusion
Number of subjects: 0
Study 11973171 — intervention group
Group type: COMPARATOR
Intervention: No insulin (Control group)
Number of subjects: 0
Study 10470991 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg 3x daily for 1 day)
Number of subjects: 38
Study 10470991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 7890074 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 6.25 mg orally twice daily for 4 days
Number of subjects: 12
Study 7890074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ACE inhibitor)
Number of subjects: 12
Study 2095164 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of 81 mval/day MgSO4 for 3 days
Number of subjects: 42
Study 2095164 — intervention group
Group type: COMPARATOR
Intervention: No infusion (Control group)
Number of subjects: 42
Study 90601 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 6
Study 90601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31678968 — intervention group
Group type: COMPARATOR
Intervention: Placebo surgery (sham surgeries)
Number of subjects: 0
Study 31678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial menisectomy
Number of subjects: 0
Study 31678968 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic subacromial decompression
Number of subjects: 0
Study 27932278 — intervention group
Group type: EXPERIMENTAL
Intervention: Spacing anti-TNF
Number of subjects: 137
Study 27932278 — intervention group
Group type: COMPARATOR
Intervention: Maintaining anti-TNF
Number of subjects: 137
Study 27932278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 137
Study 23860293 — intervention group
Group type: EXPERIMENTAL
Intervention: Corrective exercise program 4 times per week
Number of subjects: 0
Study 23860293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 23431210 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (pelvic-floor muscle exercises and bladder control strategies)
Number of subjects: 296
Study 23431210 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (bladder control strategies)
Number of subjects: 296
Study 23431210 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (pelvic-floor muscle exercises)
Number of subjects: 296
Study 23431210 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (exercise adherence predictors)
Number of subjects: 296
Study 21110732 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS
Number of subjects: 10
Study 21110732 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 10
Study 21110732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 10
Study 21110732 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 21110732 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-cephalic tDCS
Number of subjects: 10
Study 20027344 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaferon (pediatric formulation)
Number of subjects: 0
Study 17346383 — intervention group
Group type: EXPERIMENTAL
Intervention: Befriending intervention
Number of subjects: 44
Study 17346383 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 44
Study 15994143 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 252
Study 15994143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 252
Study 15994143 — intervention group
Group type: COMPARATOR
Intervention: Control (standard medical care)
Number of subjects: 252
Study 12140794 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (hypertrophic maximal strength training) for 12 weeks, initially two times, then three times a week
Number of subjects: 28
Study 12140794 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (hypertrophic maximal strength training)
Number of subjects: 28
Study 12140794 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 28
Study 9537454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with thymosin alpha1 (TA1) and interferon (IFN)
Number of subjects: 109
Study 9537454 — intervention group
Group type: COMPARATOR
Intervention: Interferon (IFN) alone
Number of subjects: 109
Study 9537454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (untreated controls)
Number of subjects: 109
Study 7852226 — intervention group
Group type: EXPERIMENTAL
Intervention: Gugulipid (1 gm)
Number of subjects: 17
Study 2531052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic blockade with metoclopramide (n = 5) during water immersion
Number of subjects: 10
Study 2531052 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic blockade with domperidone (n = 5) during water immersion
Number of subjects: 10
Study 2531052 — intervention group
Group type: COMPARATOR
Intervention: Water immersion alone (control for both groups)
Number of subjects: 10
Study 1053432 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal spray containing purified IgG from a subject with a high titre of IgG antibody to ragweed antigen E
Number of subjects: 14
Study 1053432 — intervention group
Group type: COMPARATOR
Intervention: Nasal spray containing phosphate-buffered saline (PBS) with human serum albumin
Number of subjects: 14
Study 31177131 — intervention group
Group type: EXPERIMENTAL
Intervention: Minicholecystectomy (MC), n=58
Number of subjects: 110
Study 31177131 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC), n=52
Number of subjects: 110
Study 31177131 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MC and LC groups
Number of subjects: 110
Study 26423058 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based culture-specific intervention for improving mammography utilization
Number of subjects: 136
Study 26051498 — intervention group
Group type: EXPERIMENTAL
Intervention: iLTS-D
Number of subjects: 64
Study 26051498 — intervention group
Group type: COMPARATOR
Intervention: Fastrach
Number of subjects: 64
Study 23985254 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and radiotherapy (Cap-CRT)
Number of subjects: 400
Study 23985254 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and oxaliplatin plus radiotherapy (Cap-Oxa-CRT)
Number of subjects: 400
Study 21751889 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant CGM group (12 patients on insulin pump with glucose sensor, 24 h/day)
Number of subjects: 25
Study 21751889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent CGM group (13 patients on insulin pump with intermittent glucose sensor, 14 days/month)
Number of subjects: 25
Study 21751889 — intervention group
Group type: COMPARATOR
Intervention: Constant CGM group
Number of subjects: 25
Study 21751889 — intervention group
Group type: COMPARATOR
Intervention: Intermittent CGM group
Number of subjects: 25
Study 21751889 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 25
Study 18214709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IV cyclophosphamide (LD-CYC) 500 mg/dose for six fortnightly pulses (cumulative dose 3 g) followed by azathioprine (AZA)
Number of subjects: 46
Study 18214709 — intervention group
Group type: COMPARATOR
Intervention: High-dose IV cyclophosphamide (HD-CYC) maximum of 1 g/dose for six monthly pulses followed by two quarterly pulses, followed by azathioprine (AZA)
Number of subjects: 46
Study 18214709 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IV cyclophosphamide (LD-CYC)
Number of subjects: 46
Study 18214709 — intervention group
Group type: COMPARATOR
Intervention: High-dose IV cyclophosphamide (HD-CYC)
Number of subjects: 46
Study 16769598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Number of subjects: 24
Study 16769598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 75 mg
Number of subjects: 24
Study 16769598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 2.5 mg
Number of subjects: 24
Study 16769598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg
Number of subjects: 24
Study 16769598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15446552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide and etoposide combination or carboplatin combination
Number of subjects: 0
Study 15446552 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ifosfamide and doxorubicin
Number of subjects: 0
Study 15446552 — intervention group
Group type: EXPERIMENTAL
Intervention: Total surgical excision of residual lung metastases
Number of subjects: 0
Study 11376923 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone tapering plus amantadine (200-300 mg per day)
Number of subjects: 80
Study 11376923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9422413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 303
Study 9422413 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 303
Study 8357779 — intervention group
Group type: EXPERIMENTAL
Intervention: Cicletanine (200 mg)
Number of subjects: 9
Study 8357779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2892499 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine, 50 mg (H1 receptor antagonist) and Cimetidine, 300 mg (H2 receptor antagonist)
Number of subjects: 0
Study 2892499 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 29332237 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of acetaminophen
Number of subjects: 13
Study 29332237 — intervention group
Group type: COMPARATOR
Intervention: 1 g of maltodextrin (placebo)
Number of subjects: 13
Study 27567966 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nicotine replacement therapy/placebo and contingency management for attendance/abstinence
Number of subjects: 21
Study 27567966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 26653027 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction string group
Number of subjects: 114
Study 26653027 — intervention group
Group type: COMPARATOR
Intervention: No string group
Number of subjects: 114
Study 26653027 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 114
Study 24348909 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction of the right arm (10‐20% of maximal voluntary force) with left arm passively moved by a motorized manipulandum.
Number of subjects: 20
Study 24348909 — intervention group
Group type: COMPARATOR
Intervention: Isometric contraction of the right arm (10‐20% of maximal voluntary force) with left arm remaining static.
Number of subjects: 20
Study 20876621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized colistimethate sodium (CMS) equivalent to 75 mg of colistin base in 4 mL of NSS
Number of subjects: 100
Study 20876621 — intervention group
Group type: COMPARATOR
Intervention: Nebulized sterile normal saline (NSS)
Number of subjects: 100
Study 20876621 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized colistimethate sodium (CMS)
Number of subjects: 100
Study 18096125 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (practiced the task)
Number of subjects: 30
Study 18096125 — intervention group
Group type: COMPARATOR
Intervention: Group B (viewed an error‐instruction video, practiced, followed by re‐assessment)
Number of subjects: 30
Study 18096125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 16874157 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac exercise program (HBCEP)
Number of subjects: 30
Study 16874157 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 30
Study 12811255 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation (Tx)
Number of subjects: 8
Study 12811255 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis (HD)
Number of subjects: 8
Study 12811255 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine and N‐monomethyl‐L‐arginine
Number of subjects: 8
Study 11015164 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg hydrochlorothiazide per day
Number of subjects: 320
Study 11015164 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide per day
Number of subjects: 320
Study 11015164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 8969393 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil
Number of subjects: 50
Study 8969393 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-midazolam
Number of subjects: 50
Study 8969393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 1459387 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological treatment of hypertension (NPTH)
Number of subjects: 250
Study 1459387 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacological treatments of hypertension (Control)
Number of subjects: 250
Study 4085523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine 5 mg
Number of subjects: 6
Study 4085523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine 10 mg
Number of subjects: 6
Study 4085523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine 20 mg
Number of subjects: 6
Study 30109735 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme based on healthy eating, physical exercise, and cognitive behavioural therapy
Number of subjects: 74
Study 30109735 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 30109735 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary programme
Number of subjects: 74
Study 27504006 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<120 mm Hg)
Number of subjects: 4266
Study 27504006 — intervention group
Group type: COMPARATOR
Intervention: Standard systolic blood pressure target (<140 mm Hg)
Number of subjects: 4266
Study 27504006 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension (OH)
Number of subjects: 4266
Study 27504006 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary composite outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death)
Number of subjects: 4266
Study 24323034 — intervention group
Group type: EXPERIMENTAL
Intervention: goserelin combined with dutasteride (ZD)
Number of subjects: 35
Study 24323034 — intervention group
Group type: EXPERIMENTAL
Intervention: bicalutamide and dutasteride (ZBD)
Number of subjects: 35
Study 24323034 — intervention group
Group type: EXPERIMENTAL
Intervention: bicalutamide, dutasteride, and ketoconazole (ZBDK)
Number of subjects: 35
Study 24323034 — intervention group
Group type: COMPARATOR
Intervention: combined androgen blockade with luteinizing hormone‐releasing hormone agonist and bicalutamide (Control)
Number of subjects: 35
Study 22360332 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% L-carnitine applied topically for 3 weeks
Number of subjects: 0
Study 22360332 — intervention group
Group type: COMPARATOR
Intervention: 0.5% or 1% L-carnitine in vitro
Number of subjects: 0
Study 20482535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin 100 microg
Number of subjects: 0
Study 20482535 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin 5 IU intravenously
Number of subjects: 0
Study 18382819 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy group (n = 15)
Number of subjects: 30
Study 16006908 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 shocks per minute
Number of subjects: 220
Study 16006908 — intervention group
Group type: COMPARATOR
Intervention: 120 shocks per minute
Number of subjects: 220
Study 12548201 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethindrone acetate/5 microg ethinyl estradiol
Number of subjects: 357
Study 12548201 — intervention group
Group type: COMPARATOR
Intervention: Conjugated equine estrogens/medroxyprogesterone acetate
Number of subjects: 357
Study 10611554 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 800 microg/day
Number of subjects: 30
Study 10611554 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg/day
Number of subjects: 30
Study 9050657 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic mesosalpingeal dilute vasopressin injection
Number of subjects: 40
Study 9050657 — intervention group
Group type: COMPARATOR
Intervention: No vasopressin (control group)
Number of subjects: 40
Study 1815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 5 mg orally
Number of subjects: 8
Study 1815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 10 mg orally
Number of subjects: 8
Study 1815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 20 mg orally
Number of subjects: 8
Study 1815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 0.1 mg intravenously
Number of subjects: 8
Study 1815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine 0.5 mg intravenously
Number of subjects: 8
Study 1815973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (all doses)
Number of subjects: 8
Study 6292803 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 300 mg orally
Number of subjects: 135
Study 6292803 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g intramuscularly
Number of subjects: 135
Study 6292803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 600 mg orally
Number of subjects: 135
Study 6292803 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (CTM)
Number of subjects: 135
Study 31849138 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week work-place smoking cessation group training programme with financial incentives (gift vouchers of €350 for 12 months' continuous abstinence)
Number of subjects: 604
Study 31849138 — intervention group
Group type: COMPARATOR
Intervention: 7-week work-place smoking cessation group training programme without financial incentives
Number of subjects: 604
Study 31849138 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-week work-place smoking cessation group training programme with financial incentives
Number of subjects: 604
Study 31567943 — intervention group
Group type: EXPERIMENTAL
Intervention: High VO2max group
Number of subjects: 119
Study 31567943 — intervention group
Group type: EXPERIMENTAL
Intervention: Low VO2max group
Number of subjects: 119
Study 31567943 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2max
Number of subjects: 119
Study 28940320 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention of Post‐Rape Stress (PPRS) video intervention
Number of subjects: 154
Study 28940320 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 154
Study 28940320 — intervention group
Group type: COMPARATOR
Intervention: Pleasant Imagery and Relaxation Instruction (PIRI)
Number of subjects: 154
Study 25785452 — intervention group
Group type: EXPERIMENTAL
Intervention: Group peer support
Number of subjects: 1299
Study 25785452 — intervention group
Group type: EXPERIMENTAL
Intervention: Group peer support (attended at least once)
Number of subjects: 1299
Study 25785452 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1299
Study 23455861 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation (HFCWO)
Number of subjects: 45
Study 23455861 — intervention group
Group type: COMPARATOR
Intervention: Chest physiotherapy
Number of subjects: 45
Study 21868709 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly supervised exercise training for 12 weeks
Number of subjects: 35
Study 21868709 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise training for 12 weeks
Number of subjects: 35
Study 19106795 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate for lowering blood pressure
Number of subjects: 565
Study 17003953 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology treatment
Number of subjects: 109
Study 17003953 — intervention group
Group type: COMPARATOR
Intervention: Nonspecific foot massage control
Number of subjects: 109
Study 15470966 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning light (6000 lux) for 1.5 hours daily for 4 weeks
Number of subjects: 26
Study 15470966 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening light (6000 lux) for 1.5 hours daily for 4 weeks
Number of subjects: 26
Study 15470966 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (sham negative ion generators) for 1.5 hours daily for 4 weeks
Number of subjects: 26
Study 15470966 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (morning light, evening light, placebo)
Number of subjects: 26
Study 15259283 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/NETA (estradiol 2 mg plus norethisterone acetate 1 mg)
Number of subjects: 91
Study 15259283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 91